RivoceranibHaemafecia following off-label treatment: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1721卷 / 1期

关键词：

D O I：

10.1007/s40278-018-52300-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：263 / 263

相关论文

共 50 条

[1] HydroxychloroquineHepatotoxicity following off-label treatment: case report
[J]. Reactions Weekly, 2020, 1812 (1) : 148 - 148
[2] PembrolizumabNeutropenia following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1851 (1) : 288 - 288
[3] BexaroteneTransaminitis following an off-label treatment: case report
[J]. Reactions Weekly, 2019, 1741 (1) : 59 - 59
[4] VenetoclaxNeutropenia following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1849 (1) : 412 - 412
[5] MethylprednisoloneStrongyloidiasis following off-label treatment: case report
[J]. Reactions Weekly, 2022, 1893 (1) : 213 - 213
[6] TocilizumabPulmonary infection following off-label treatment: case report
[J]. Reactions Weekly, 2020, 1799 (1) : 353 - 353
[7] DexamethasoneLack of efficacy following an off-label treatment: case report
[J]. Reactions Weekly, 2022, 1924 (1) : 189 - 189
[8] TriamcinoloneOcular hypertension following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1883 (1) : 351 - 351
[9] HydrocortisoneGastrointestinal mucormycosis following off-label treatment: case report
[J]. Reactions Weekly, 2022, 1911 (1) : 225 - 225
[10] CannabidiolVarious toxicities following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1860 (1) : 103 - 103

← 1 2 3 4 5 →